RxDoctor Payments Data

Paul Fallon, MD

Psychiatry · Georgetown, MANPI 1093889206

Payments from drug & device makers

$727in general payments, 2019–2025

Across 44 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$265
  • AbbVie$171
  • Johnson & Johnson$69
  • Sunovion Pharmaceuticals Inc.$61
  • Takeda Pharmaceuticals U.S.A., Inc.$31
  • E.r. Squibb & Sons, L.L.C.$27
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$69696%
  • Education$314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$727 in reported general payments places this provider in the 80th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$89,010
Medicare patients
228
Services billed
1,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$59,802
AristadaAripiprazole Lauroxil13$40,882
Risperdal ConstaRisperidone Microspheres12$30,038
CaplytaLumateperone Tosylate12$22,334
RexultiBrexpiprazole13$22,206
TrintellixVortioxetine Hydrobromide34$19,858
VraylarCariprazine Hcl11$16,335
Depakote ErDivalproex Sodium14$8,205
Atomoxetine Hcl25$7,948
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine129$5,401
Adderall XrDextroamphetamine/Amphetamine13$5,233
BelsomraSuvorexant12$4,839
Clozapine68$4,735
Lisdexamfetamine Dimesylate16$4,545
Quetiapine Fumarate204$3,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$69$89,84032 claims
Alkermes, Inc.Aristada$18$40,88213 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$19$22,33412 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$31$19,85834 claims
AbbVieVraylar$171$16,33511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in Georgetown

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →